Список литературы

Поставить закладку

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242-268.
Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology. 2003 Apr 1;60(8 Suppl 3):2-7.
Lewis R. A. Chronic inflammatory demyelinating polyneuropathy //Neurologic clinics. – 2007. – Т. 25. – №. 1. – С. 71-87.
Cornblath D. R. et al. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies //Journal of neuroimmunology. – 1990. – Т. 26. – №. 2. – С. 113-118.
Schmidt B. et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy //Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine.–1996.–Т.19. – №.4. – С.474-487.
Pollard J. D. et al. Activated T cells of nonneural specificity open the blood nerve barrier to circulating antibody //Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. – 1995. – Т. 37. – №. 4. – С. 467-475.
Dalakas M. C., Engel W. K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy //Archives of neurology. – 1980. – Т. 37. – №. 10. – С. 637-640.
Mathey E. K. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype //J Neurol Neurosurg Psychiatry.–2015.–Т. 86.–№. 9. – С. 973-985.
Dyck P. J. B., Tracy J. A. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy //Mayo Clinic Proceedings. – Elsevier, 2018. – Т. 93. – №. 6. – С. 777-793.
Querol L. et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy //Annals of neurology. – 2013. – Т. 73. – №. 3. – С. 370-380.
Doppler K. et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies //J Neurol Neurosurg Psychiatry. – 2015. – Т. 86. – №. 7. – С. 720-728.
Querol L. et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg //Neurology. – 2014. – Т. 82. – №. 10. – С. 879-886.
Uncini A., Vallat J. M. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground //J Neurol Neurosurg Psychiatry. – 2018. – Т. 89. – №. 6. – С. 627-635.
Delmont E. et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy //Brain. – 2017. – Т. 140. – №. 7. – С. 1851-1858.
Broers M.C., Bunschoten C. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019;52:161–172
Rajabally Y.A., Simpson B.S., Beri S. et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39(4):432–8.
Попова Т.Е., Шнайдер Н.А., Петрова М.М., Николаева Т.Я., Кантимирова Е.А. Эпидемиология хронической воспалительной демиелинизирующей полиневропатии за рубежом и в России. Нервно-мышечные болезни. 2015;5(2):10-15. [Popova T.E., Shnayder N.A., Petrova M.M., Nikolaeva T.Y., Kantimirova E.A. Epidemiology of chronic inflammatory demyelinating polyneuropathy abroad and in Russia. Neuromuscular Diseases. 2015;5(2):10-15. (In Russ.)].
Супонева Н.А, Никитин С.С., Пирадов М.А., Меркулова Д.М. Хроническая воспалительная демиелинизирующая полиневропатия с острым началом и дыхательной недостаточностью. Нервные болезни 2007;(1):40–4. [Suponeva N.A., Nikitin S.S., Piradov M.A., Merkulova D.M. Chronic inflammatory demyelinating polyneuropathy with acute onset and respiratory failure. Nervnye bolezni = Nervous Diseases 2007;(1):40–4. (In Russ.)].
Lehmann H. C., Burke D., Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment //J Neurol Neurosurg Psychiatry. – 2019. – С. jnnp-2019-320314.
Viala K. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy //Journal of the peripheral nervous system. – 2010. – Т. 15. – №. 1. – С. 50-56.
Rajabally Y. A., Chavada G. Lewis–Sumner syndrome of pure upper-limb onset: Diagnostic, prognostic, and therapeutic features //Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. – 2009. – Т. 39. – №. 2. – С. 206-220.
Ayrignac X. et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? //Muscle & nerve. – 2013. – Т. 48. – №. 5. – С. 727-732.
Katz J. S. et al. Distal acquired demyelinating symmetric neuropathy //Neurology. – 2000. – Т. 54. – №. 3. – С. 615-615.
Ruts L. et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study //Neurology. – 2010. – Т. 74. – №. 21. – С. 1680-1686.
Kimura A, Sakurai T, Koumura A et al. Motor - dominant chronic inflammatory demyelinating polyneuropathy. JNeurol. 2010;257(4):621-9.
Devaux J. J. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy //Neurology. – 2016. – Т. 86. – №. 9. – С. 800-807.
Roach С., Pasnoor М. et al. Evaluation of CIDP Diagnostic Criteria and Treatment Responses. Neurology Apr 2016, 86 (16 Supplement) P3.141
Rajabally YA, Nicolas G, Piéret F, Bouche P, Van den Bergh PY. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1364-8.
Viala K., Maisonobe T. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1364-8.
Gorson K.C. An update on the management of chronic inflammatory demyelinating polyneuropathy // Ther. Adv. Neurol. Disord. 2012. Vol 5. P. 359-373
Neal J.W., Gasque P. The role of primary infection of Schwann cells in the aetiology of infective inflammatory neuropathies // Journal of Infection. 2016. 73(5): 402-418.
Breiner A., Bourque P.R., Allen J.A. Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve. 2019 Aug;60(2):180-183
Breiner A, Moher D, Brooks J, Cheng W, Hegen H, Deisenhammer F, McCudden CR, Bourque PR. Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review. J Neurol 2019;266(3):616-624.
Lucke, I. M., Peric, S., van Lieverloo et al. (2018). Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 23(1), 49–54.
Allen J.A., Lewis R.A. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015 Aug 11;85(6):498-504.
Brannagan T. H. Current diagnosis of CIDP: the need for biomarkers. Journal of the Peripheral Nervous System; 2011- 16, 3–13.
Rajabally YA, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst 2005; 10: 282–292
Sumner AJ (1994). Electrophysiology of the inflammatory demyelinating polyneuropathies. Baillieres Clin Neurol 3:25–43
Rajabally YA, Narasimhan M. Distribution, clinical correlates and significance of axonal loss and demyelination in chronic in flammatory demyelinating polyneuropathy. Eur J Neurol. 2011 Feb;18(2):293-9.
Rajabally YA, Jacob S. Proximal nerve conduction studies in of chronic inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2006; 117: 2079–2084
Tanaka K, Mori N, Yokota Y, Suenaga T. MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy: a single - institution, retrospective case -control study. BMJ Open 2013; 3: e003443
Tazawa K., Matsuda M., Yoshida T. et al. Spinal nerve root hypertrophy on MRI: clinical significance in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. 2008;47(23):2019-24.
Lozeron P, Lacour MC, Vandendries C, et al. Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies. J Neurol Sci 2016; 360: 170–75
Kronlage M, Bäumer P, Pitarokoili K, et al. Large coverage MR neurography in CIDP: diagnostic accuracy and electrophysiological correlation. J Neurol 2017; 264: 1434–43
Goedee H.S., Brekelmansa G.J.F., van Asseldonkb J.T.H. et al. High resolution sonography in the evaluation of the peripheral nervous system in polyneuropathy – a review of the literature. European Journal of Neurology 2013, 20: 1342–1351.
Kerasnoudis A, Pitarokoili K., Haghikia A. et al. Nerve ultrasound protocol in differentiating chronic immune-mediated neuropathies. Muscle Nerve, 2016; 54:5; 864-871.
Pitarokoili K, Kronlage M, Baumer P, et al. High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord 2018; 11: 1756286418759974
Zaidman C.M., Harms M.B., Pestronk A. Ultrasound of inherited vs. acquired demyelinating polyneuropathies. J Neurol. 2013; 260(12):3115-21.
Padua L., Granata G., Sabatelli M. et al. Heterogeneity of root and nerve ultrasound pattern in CIDP patients. Clin. Neurophysiol, 2014;125:160–165.
Grimm A, Schubert V, Axer H, Ziemann U. Giant nerves in chronic inflammatory polyradiculoneuropathy. Muscle Nerve. 2017 Feb;55(2):285-289.
Devic P, Petiot P Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral demyelination. Muscle Nerve. 2016 Jan;53(1):78-83.
Kulkarni GB, Mahadevan A, Taly AB, Nalini A, Shankar S K. Sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy: Are supportive pathologic criteria useful in diagnosis? Neurol India 2010;58:542-8
Bosboom WM1, van den Berg LH, Franssen H, Giesbergen PC, Flach HZ, van Putten AM, Veldman H, Wokke JH. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain. 2001 Dec;124(Pt 12):2427-38
Mathis S., Magy L., Le Masson G. et al. Value of nerve biopsy in the management of peripheral neuropathies, Expert Review of Neurotherapeutics 2018;18(7):589-602.
Marek T, Howe BM, Amrami KK, Spinner RJ. From targeted fascicular biopsy of major nerve to targeted cutaneous nerve biopsy: implementing clinical anatomy can catalyze a paradigm shift. Clin Anat 2018; 31:616–621.
Пирадов М.А., Супонева Н.А., Гришина Д.А. / Полинейропатии: алгоритмы диагностики и лечения - Москва: Горячая линия - Телеком, 2019. 248 с.
Пирадов М.А., Супонева Н.А., Гришина Д.А., Павлов Э.В. / Электронейромиография: алгоритмы и рекомендации при полинейропатиях – Москва: Горячая линия – Телеком, 2021. 198 с.
French CIDP Study Group. Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):115-8.
Hend Azhary, Muhammad U., Farooq M.U., Bhanushali M. et al. Peripheral neuropathy: differential diagnosis and management // Am Fam Physician. 2010; 81 (7): 887–892.
Imreova H., Pura M. Differential diagnosis of peripheral neuropathy // Cas Lek Cesk. 2005; 144 (9): 628–635.
Ann Noelle Poncelet. An Algorithm for the evaluation of peripheral neuropathy. Am Fam Physician. 1998;57(4):755-764.
Oaklander AL, Lunn MPT, Hughes RAC, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD010369.
Perez E. E., Orange J. S., Bonilla F. et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017;139(3):S1–S46.
Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15: 893–908
Rachid R., Bonilla F. A. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012;129(3):628–34.
van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209–212
Vermeulen M, van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36–39
Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment (IVIg) in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind placebo-controlled cross-over study. Brain 1996; 119: 1067–1078
Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445–449
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; 1: CD001797
Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate chromatography purified) for the treatment of of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol 2008; 7: 136–144
Merkies IS, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 2009; 72:1337–1344
Hughes, R., Bensa, S., Willison, H., Van Den Bergh et al. (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology, 50(2), 195–201
Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017 Nov 29;11:CD002062.
van Lieverloo GGA, Peric S, Doneddu PE, Gallia F, Nikolic A, Wieske L, Verhamme C, van Schaik IN, Nobile-Orazio E, Basta I, Eftimov F. Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018 Sep;265(9):2052-2059.
Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012; 78(14):1079–84.
Molenaar DS, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997; 62: 388–390
Press R, Hiew FL, Rajabally YA. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol Scand. 2016 Apr;133(4):228-38.
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, RaeGrant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76(3):294-300.
Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015 Aug 25;(8):CD003906
Pham HP, Schwartz J. Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med. 2019 Nov;48(11 Pt 2):338-346.
Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055–1066
Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 Mar;61(3):316-324.
van Schaik IN, Bril V, van Geloven N et al. PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46.
Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. Muscle Nerve. 2017 Jun;55(6): 802-809.
van Schaik IN, Mielke O, Bril V et al. PATH study group. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019; 6(5): e590.
Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010; 49(3): 239-48.
Albulaihe H, Alabdali M, Alsulaiman A. et al. Disease activity in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2016; 369 (10): 204-209.
Супонева Н. А., Наумова Е. С., Гнедовская Е. В. Хроническая воспалительная демиелинизирующая полинейропатия у взрослых: принципы диагностики и терапия первой линии. Нервно-мышечные болезни. 2016; 6 (1): 44-53.
Lopate G., Pestronk A., Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Archives of neurology. 2005; 62 (2): 249-254. Schaik IN, Eftimov F, Doorn PA, Brusse E, Berg LH, Pol WL, et al. Pulsed high‐dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double‐blind, randomised, controlled trial. Lancet Neurology 2010;9(3):245‐53.
Антонова К.В., Супонева Н.А., Щербакова Н.И. и др. Глюкокортикоидиндуцированный остеопороз у неврологических больных: мероприятия по профилактике и лечению. Нервно-мышечные болезни. 2017; 7(2):10-20.
Hu J, Sun C, Lu J et al. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. J Neurol. 2022; 269(3): 1250-1263.
Chaganti S, Hannaford A, Vucic S. Rituximab in chronic immune mediated neuropathies: a systematic review. Neuromuscul Disord. 2022; 32(8) :621-627.
Maisonobe T, Jaccard A. [Chronic inflammatory demyelinating polyneuropathy (CIDP) revealing an associated disease diagnostic and therapeutic pitfalls]. Rev Neurol (Paris). 2007 Sep;163 Spec No 1:3S61-7.
Dyck P.J., Daube J., O"Brien P. Plasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. N Engl J Med 1986; 314(2): 461-465.
Boedecker S.C., Luessi F., Engel S. Immunoadsorption and plasma exchange—Efficient treatment options for neurological autoimmune diseases. Journal of Clinical Apheresis. 2022; 37 (1): 70-81.
Guptill JT, Runken MC, Eaddy M, Lunacsek O, Fuldeore RM. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis. Am Health Drug Benefits. 2019 May;12(3): 127-135.
Mahdi-Rogers M, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013 Jun 14;(6):CD003280.
Арестова А.С., Мельник Е.А., Зайцев А.Б. и др. Шкала «Этиология и лечение воспалительной нейропатии» (Inflammatory Neuropathy Cause and Treatment, INCAT) для оценки степени инвалидизации у больных хронической воспалительной демиелинизирующей полинейропатией: лингвокультурная адаптация в России. Нервно-мышечные болезни. 2021;11(4):26-33.
Merkies I., Schmitz P., van der Meché F., van Doorn P. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology. 2000; 54(4): 943-949.
Dyck P.J., Sherman W.R., Hallcher L.M. et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Annals of Neurology. 1980; 8(6): 590-596.
van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011; 76(4): 337-345.
Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, Briani C, Fazio R, Jann S, Matà S, Sabatelli M, Nobile-Orazio E; Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011 Dec;18(12):1417-21.
Muley SA, Jacobsen B, Parry G et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 Jan 10.
MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert KE, Evanovitch D, Heddle NM, Arnold DM. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion. 2018 Nov;58(11):2729-2735.
Bjelica B., Peric S., Bozovic I. et al. One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. 2019; 24(2): 180-186.
Roux T., Debs R., Maisonobe T. et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst. 2018; 23(4): 235-240.
Laudati C, Clark C, Knezevic A. et al. Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. Clin J Oncol Nurs. 2018; 22(4): 407-414.
Swan J.T., Zaghloul H.A., Cox J.E. et al. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits. Pharmacotherapy. 2014; 34(7): 686-94.
Kozow L., Pupe C., Nascimento O. Chronic inflammatory demyelinating polyneurophaty: assessment of the cognitive function and quality of life. Arq Neuropsiquiatr 2022; 80(12): 1246-1253.
Bozovic, I., Kacar, A., Peric, S. et al. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2017; 264: 2481–2486.
Michaelides A, Hadden RDM, Sarrigiannis PG, Hadjivassiliou M, Zis P. Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Pain Ther. 2019 Dec;8(2):177-185.
Cruccua G., Sommer C. et al. EFNS guidelines on neuropathic pain assessment: revised 2009. European Journal of Neurology 2010, 17: 1010–1018.
Doneddu P. E., Bianchi E. et al. European Journal of Neurology. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. 2019: 0:1-8
Garssen MP, Bussmann JB, Schmitz PI et al. Physical training and fatigue, fitness and quality of life in Guillain-Barre syndrome and CIDP. Neurology 63(12), 2393–2395 (2004)
Graham RC, Hughes RA, White CM. A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. J. Neurol. 254(2), 228–235 (2007)
Markvardsen L. H., Overgaard, K., Heje, K., Sindrup, S. H., Christiansen, I., Vissing, J., & Andersen, H. (2018). Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle & Nerve, 57(1), 70–76
Marwale A, Gautam M, Murambikar G, Bhise M, Soni A. Depression with Chronic Inflammatory Demyelinating Polyneuropathy. Indian Journal of Psychological Medicine. 2018;40(6):580-583.
Merkies I.S.J., Kieseier B.C. Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eur Neurol (2016) 75 (3-4): 199–206.
Klehmet, J., Tackenberg, B., Haas, J. et al. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy. BMC Neurol. 2023; 207.
Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008; 38(2): 1036-1045
Querol L, Rojas-Garcia R et al. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve. 2013 Dec;48(6):870-6. doi: 10.1002/mus.23843. Epub 2013 Sep 11
Bunschoten C., Blomkwist‐Markens, P. H., Horemans, A., Doorn, P. A., & Jacobs, B. C. (2019). Clinical factors, diagnostic delay and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. doi:10.1111/jns.12344
Kuwabara S, Misawa S et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006 Jan; 77(1): 66–70
В соответствии с приказом Министерства здравоохранения РФ от 31 мая 2021 г. №557н «Об утверждении классификации природных лечебных ресурсов, медицинских показаний и противопоказаний к их применению в лечебно-профилактических целях».
Приказ Министерства здравоохранения Российской Федерации от 31 июля 2020 г. №788н "Об утверждении Порядка организации медицинской реабилитации взрослых".